Company intelligence / Profile preview
Singlomics Biopharmaceuticals
Beijing, Beijing, Chinasinglomics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Singlomics has advanced multiple monoclonal antibody programs, including SARS-CoV-2 neutralizing antibodies reaching up to Phase 2 clinical development. Programs targeting IL-1RAP and TREM-1 for oncology and immunology remain in preclinical stages. Their anti-COVID-19 antibodies, licensed to BeiGene, demonstrated strong preclinical efficacy and progressed to Phase 1/2 trials[2][5][7].
- Therapeutic areas
- OncologyInfectious DiseasesImmunology
- Modalities
- Monoclonal antibodyBiologic
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
BeiGene
Beyond the preview
Go deeper on Singlomics Biopharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Singlomics Biopharmaceuticals.